← BioTransfer GEO Dataset Finder
GEO series

Genome-Wide CRISPR-Cas9 screening identifies BRAF inhibitor as a sensitizer of dasatinib in treating T-acute lymphoblastic leukemia

GSE218078 Homo sapiens Expression profiling by high throughput sequencing 9 samples Submitted 2025/06/01 Platform GPL23227
Summary
T-cell acute lymphoblastic leukemia is an aggressive hematologic tumor with fewer treatment strategies. Dasatinib, an FDA-approved tyrosine kinase inhibitor applied in chronic myelogenous leukemia and acute lymphoblastic leukemia with Philadelphia chromosome-positive has been utilized in T-ALL for cure but the clinical outcomes are not satisfied, calling for further investigation on the mechanism and potential combinations to overcome resistance. In this study, we performed a genome-wide CRISPR-Cas9 screening and identified the MAPK pathway as an essential regulator of sensitivity to dasatinib. Then we confirmed that the inhibition of the MAPK pathway by dabrafenib could sensitize T-ALL cells to dasatinib in vitro and reveal the underlying mechanism by RNA sequencing. Together, we put forward a promising combining strategy for T-ALL.
This dataset
Download

Direct links to NCBI, no account and no request form: the whole study as GSE218078_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 9 samples. Raw sequencing reads are also available from ENA.

Also filed as BioProject PRJNA902286. Searching any of these in the dataset finder brings you back here.

Samples in this study

The sample list for this study is not cached yet. Press Sort into groups and it will be fetched from NCBI.

+ 9 more — browse all 9 samples with per-sample file links →

Similar datasets

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.